Abstract:OBJECTIVE: To provide healthcare professionals with updated guidance in the use of novel preventive and acute treatments for migraine in adults.BACKGROUND: The principles of preventive and acute pharmacotherapy for patients with migraine have been outlined previously, but the emergence of new technologies and treatments, as well as new formulations of previously established treatments, has created a need for an updated guidance on the preventive and acute treatment of migraine.METHODS: This statement is based on a review of existing guidelines and principles for preventive and acute treatment of migraine, as well as the results of recent clinical trials of drugs and devices for these indications. Input was sought from health insurance providers, employers, pharmacy benefit service companies, device manufacturers, pharmaceutical and biotechnology companies, patients, and patient advocates. Expert clinicians and researchers in the field of headache medicine from across North America and the European Union provided input and feedback.RESULTS: The principles of pharmacologic preventive treatment of migraine with oral treatments have been as follows: use evidence-based treatments when possible and appropriate; start with a low dose and titrate slowly; reach a therapeutic dose if possible; allow for an adequate treatment trial duration; establish expectations of therapeutic response and adverse events; and maximize adherence. Newer injectable treatments may work faster and may not need titration. The principles of acute treatment include: use evidence-based treatments when possible and appropriate; treat early after the onset of a migraine attack; choose a nonoral route of administration for selected patients; account for tolerability and safety issues; consider self-administered rescue treatments; and avoid overuse of acute medications. Neuromodulation and biobehavioral therapy may be appropriate for preventive and acute treatment, depending on the needs of individual patients. Neuromodulation may be useful for patients who prefer nondrug therapies or who respond poorly, cannot tolerate, or have contraindications to pharmacotherapy.CONCLUSIONS: This statement updates prior recommendations and outlines the indications for initiating, continuing, combining, and switching preventive and acute treatments of migraine.

Pharmacological management of migraine: current strategies and future directions

Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends

The pathophysiological and pharmacological basis of current drug treatment of migraine headache

Migraine Treatment: Towards New Pharmacological Targets

Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

The pathophysiology of migraine: implications for clinical management

Role of Phytocompounds for Effective Management of Migraine: Current and Future Prospectives

Migraine Treatment: When, Why, and How to Introduce Antimigraine Therapies

Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy

Potential treatment targets for migraine: emerging options and future prospects

Novel Therapeutic Targets for Migraine

Future targets for migraine treatment beyond CGRP

New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication

Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

Preventive and abortive treatment of migraine with traditional drugs. The state of the art

International Headache Society global practice recommendations for the acute pharmacological treatment of migraine

New Oral Drugs for Migraine

An update on migraine

Migraine: Advances in the Pathogenesis and Treatment

Migraine Management in Medically Complex Patients: a Narrative Review